daily dosing

DRUG2 trials

Sponsors

HIV Prevention Trials Network, Radboud University Medical Center

Conditions

Acute Graft Versus Host Disease Grade II-IVAcute Myeloid LeucaemiaAllogeneic Stem Cell TransplantHIV InfectionsMyelo Dysplastic Syndrome

Phase 2

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

CompletedNCT01327651

HIV Prevention Trials NetworkHIV Infections

Start: 2011-08-31End: 2014-12-31Updated: 2025-03-27

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

CompletedNCT02172768

Radboud University Medical CenterAcute Graft Versus Host Disease Grade II-IV, Acute Myeloid Leucaemia, Allogeneic Stem Cell Transplant +1

Start: 2014-10-31End: 2016-07-31Updated: 2020-12-08

Related Papers

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study

Clinical Infectious Diseases2018-01-2655 citations

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

2017-10-03103 citations